168Retinal,vitreousandmaculardisorders
retinalcapillaryblood ow,retinalandvitreoushemor-rhage,reducedvisualacuity,andultimately,blindness.
Proliferativediabeticretinopathy
VEGFisoneofmanyproin ammatorymoleculesimpli-catedintheearlystagesofdiabeticretinopathy,evenbeforeitenterstheproliferative(PDR)stage[38],andtheuseofanti-VEGFagentshasshownpotentialasatreatmentoptionforPDRaswellasDME.PegaptanibsodiumisaPEGylated28-nucleotideaptamerthatspeci callytargetstheVEGF-165isoform(Table2).IthasbeenevaluatedasanadjuncttherapyinPDRrefrac-torytolasertreatmentandassociatedwithdecreasedretinalthickness,reductioninleakageandvitreoushemorrhage,andsomebene cialeffectonvisualacuity[39,40].However,theseweresmall(n¼5–13)retrospec-tivestudiesthatusedvarioustreatmentregimens,andrequirecon rmationinlarger,prospective,randomizedtrials.Aretrospectiveanalysisofarandomized,controlledclinicaltrialevaluatingpegaptanibfortreatmentofDMEshowedthatof16patientswithretinalneovasculariza-tion,eightof13(62%)whoreceivedpegaptanib(threeinjectionsof0.3,1,or3mgover12weeks),whereasnoneofthethreepatientsintheshamgroupshowedeitherregressionofneovascularizationonfundusphotographsorregressionorabsenceof uoresceinleakagefromneovascularization(orboth)at36weeks[41].
Anumberofcasestudieshavedemonstratedthatoff-labelintravitrealbevacizumabcancauseregressionofneovascularizationintheiris,disc,andretina,andreducevascularleakageassociatedwithdiabeticretinopathy[42–46].Aninterventionalcaseseriesstudyevaluatedbevacizumab(1.25mg)in19patientswithperipheralretinalischemiaindiabeticretinopathy[47].At1-monthfollow-up,visualacuityhadimproved(P¼0.08),andtherewasangiographicevidenceofasigni cantdecreaseinmeanperipheralretinalischemiaattheearlyphase(P¼0.02)andlatephase(P<0.001),althoughnochangewasnotedinretinalthicknessmeasuredbyopticalcoher-encetomography(OCT).TheseresultsindicatedthatbevacizumabmaybeaviabletreatmentoptionforretinalischemiainPDR.Theef cacyofintravitrealbevacizu-mabinPDRiscurrentlybeingevaluatedinaphaseIIInonrandomized,open-label,uncontrolledclinicalstudyinIranandaphaseII/IIIrandomized,open-label,con-trolledclinicalstudyinMexico.
Diabeticmacularedema
Apilotstudyofmonthlyintravitrealranibizumab(0.3or0.5mg)demonstratedthatranibizumabcanreducecen-tralretinalthicknessandincreasevisualacuityinDME.Atmonth3,ranibizumabhadimprovedvisualacuitybyatleast15lettersin40%andbyatleast10lettersin50%ofpatients[49].Inanonrandomizedtrialinvolving10patientswithDME,0.5mgranibizumabwasinjectedintravitreallyatmonths0,1,2,4,and6(atotalof veinjectionsperpatient)[50].At7months(1monthafterthe fthinjection),themedianandmeanreductionsinexcessfovealthicknesswere261and246mm,respect-ively(an85%reductioncomparedwithbaseline;P¼0.005).Themacularvolumewas7.47mm3,reducedby1.75mm3(77%oftheexcessmacularvolumeatbase-line;P¼0.009).Meanvisualacuitywas40.4letters(20/40),animprovementof12.3letters(P¼0.005).Theinjectionswerewelltolerated,withnoocularorsystemicadverseevents[50].Tworandomized,double-masked,placebo-controlledphaseIIIstudiesofranibizumabinDMEwithcenterinvolvement[studyofranibizumabinjectioninsubjectswithclinicallysigni cantmacularedemawithcenterinvolvementsecondarytodiabetesmellitus(RISE),ranibizumabinjectioninsubjectswithclinicallysigni cantwithmacularedema.centerinvolve-mentsecondarytodiabetesmellitus(RIDE)arecur-rentlyongoing[51].
Aconsecutivecaseseriesstudyof10eyesshowedthat1monthafterthreeinjectionsofbevacizumab(1mgevery6weeks),therewasagainofatleast10lettersin40%ofeyes,alongwithareductioninmeanfovealthicknessof45mm,butwithoutnormalizationoffovealandmacularthickness[52 ].Aprospective,placebo-controlled,ran-domizedclinicaltrialevaluatedbevacizumab(threeinjectionsof1.25mgat6-weekintervals)eitherasmono-therapyorincombinationwithintravitrealtriamcinoloneacetonidein115eyesin101patientswithrefractoryDME[53 ].Atweek24,centralmacularthickness(CMT)measurementsbyOCTweresigni cantlyreducedwithbevacizumabmonotherapy(meanchangeofÀ95.7mm)andwithcombinationtherapy(meanchangeofÀ92.1mm);thesechangesweresigni cantwhencomparedwithachangeofþ34.9mmintheshamcontrolgroups(monotherapy,P¼0.012;combinationtherapy,P¼0.022).Signi cantgainsinvisualacuitywerealsonotedcomparedwiththecontrolgroup(mono-therapy,P¼0.01;combinationtherapy,P¼0.006).Theadditionoftriamcinoloneinthisstudyhadnosigni canteffectonanatomicresults,butdidresultinatrendtowardearliervisualimprovements.Similaroverallresultswerealsofoundinanotherrandomizedstudy[54].Asimilarprospective,longitudinalcaseseriesdemonstratedthateveninpatientswithchronicdiffuseischemicDME(N¼126),treatmentwithintravitrealbevacizumab(1.25mg)reducedthemeanCMTby89and106mmafter6and12months,respectively(P<0.001forboth),
InaphaseIItrialofpatientswithDME,0.3mgpegap-tanibsodiumtherapyadministeredevery6weeks(threetosixtotalinjections)resultedinsigni cantlybettergainsinvisualacuity(34versus10%!10-lettergain;P¼0.003)andsigni cantlygreaterdecreasesincentralretinalthick-nesscomparedwithshamtreatment(68versus4mmdecrease;P¼0.02)[48].
therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and ...
anti-vascular endothelial growth factor (VEGF) ...found in human plasma and serum and ocular ...(Avastin) therapy for neovascular age-related ...
anti-vascular endothelial growth factor therapy – bevacizumab Acta Ophthalmol....It has been known that ocular diseases in which in?ammatory and autoimmune...
therapy or having an accompanying ocular disease. ...therapy for neovascular age - related macular ... an anti-vascular endothelial growth factor antigen...
(Macugen ) TM 1 The Impact of Neovascular AMD ...Injection – First Anti-VEGF Therapy for the Eye...Vascular Endothelial Growth Factor (VEGF) Vascular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
热门文档